<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502876</url>
  </required_header>
  <id_info>
    <org_study_id>RESISTANCE A L'IBRUTINIB</org_study_id>
    <nct_id>NCT03502876</nct_id>
  </id_info>
  <brief_title>Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL</brief_title>
  <official_title>Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL): Analysis of Real-life Data: &quot;Snapshot&quot; at 3 Years From the End of Ibrutinib ATU. A National Study of the FILO-LLC Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the mutational profile of the residual clone and the distribution of lymphocyte
      subpopulations at 3 years of treatment with ibrutinib

      This project has an epidemiological part: to establish the percentage of patients, in a
      real-life situation, still undergoing treatment 3 years after its initiation, as well as a
      biological part: to determine the evolution of the clone and the prevalence of BTK mutations
      and PLCg2 in the absence of clinical or biological criteria for scalability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observationnal and biological study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Ibrutinib resistance</measure>
    <time_frame>under treatment at 3 years of ibrutinib</time_frame>
    <description>In the long term, this study will help to draft new recommendations from FILO-LLC concerning the detection of resistance and the management of patients.</description>
  </primary_outcome>
  <enrollment type="Actual">198</enrollment>
  <condition>B Cell Chronic Lymphocytic Leukemia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      collection of a blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CLL and treated by ibrutinib in the ATU
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients included in the ATU (epidemiology)

          -  under treatment at 3 years of ibrutinib

          -  more than 18 years old

        Exclusion Criteria:

          -  no ibrutinib treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Florence CYMBALISTA, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FILO French Innovative Leukemia Organization</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Project manager</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO internet site</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

